Literature DB >> 6501802

Simultaneous radioimmunoassay for plasma arginine-vasopressin and oxytocin using DEAE Sephadex A 25 extraction.

P Chiodera, F Louis, J J Legros.   

Abstract

A sensitive and specific radioimmunoassay method for simultaneous measurement of plasma arginine vasopressin (AVP) and oxytocin (OT) has been developed utilizing an extraction technique on DEAE Sephadex A25. This procedure resulted in mean recoveries of 70.7% (AVP) and 65.4% (OT) in the peptide range of 5 to 100 pg/4 ml. The sensitivity of the assay is 0.5 pg/tube for AVP and 2 pg/tube for OT. The lower limit of detection for plasma extracts was 1.2 pg AVP/ml and 5 pg OT/ml plasma. Employing this method in normal human non smokers and ad libitum fluid the basal levels (mean +/- SE) of plasma AVP are 3.5 +/- 0.2 pg/ml in males and 4.6 +/- 0.4 pg/ml in females and the basal concentrations of plasma OT are 5.1 +/- 0.3 pg/ml in males and 5.4 +/- 0.3 pg/ml in females. Dehydration and water loading produced significant changes in plasma AVP and OT concentrations and a significant correlation exists between plasma AVP and plasma (r = 0.96, p less than 0.001) and urinary (r = 0.84, p less than 0.01) osmolality, but not between plasma OT concentrations and plasma (r = 0.11, NS) and urinary (r = 0.27, NS) osmolality. These results suggest that a wide range of physiological and pathophysiological changes in plasma AVP and OT can be simultaneously measured by the extraction procedure and the radioimmunoassay described.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6501802     DOI: 10.1007/BF03351004

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  20 in total

1.  Diurnal variation of plasma vasopressin in man.

Authors:  C P George; F H Messerli; J Genest; W Nowaczynski; R Boucher; M Kuchel Orofo-Oftega
Journal:  J Clin Endocrinol Metab       Date:  1975-08       Impact factor: 5.958

2.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

3.  A radioimmunoassay for plasma arginine-vasopressin in man and dog: application to physiological and pathological states.

Authors:  J J Morton; P L Padfield; M L Forsling
Journal:  J Endocrinol       Date:  1975-06       Impact factor: 4.286

4.  Central, renal and adrenal effects of lithium in man.

Authors:  P D Miller; S L Dubovsky; K M McDonald; F H Katz; G L Robertson; R W Schrier
Journal:  Am J Med       Date:  1979-05       Impact factor: 4.965

5.  Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays.

Authors:  B Desbuquois; G D Aurbach
Journal:  J Clin Endocrinol Metab       Date:  1971-11       Impact factor: 5.958

6.  Radioimmunoassay of vasopressin in unextracted plasma.

Authors:  F Fyhrquist; M Wallenius; H J Hollemans
Journal:  Scand J Clin Lab Invest       Date:  1976-12       Impact factor: 1.713

7.  Immunochemical studies with lysine vasopressin.

Authors:  M A Permutt; C W Parker; R D Utiger
Journal:  Endocrinology       Date:  1966-04       Impact factor: 4.736

8.  The circulating vasopressinase of pregnancy: species comparison with radioimmunoassay.

Authors:  A A Rosenbloom; J Sack; D A Fisher
Journal:  Am J Obstet Gynecol       Date:  1975-02-01       Impact factor: 8.661

9.  Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma.

Authors:  G L Robertson; E A Mahr; S Athar; T Sinha
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

10.  Plasma vasopressin and human neurophysins in physiological and pathological states associated with changes in vasopressin secretion.

Authors:  P T Pullan; B H Clappison; C I Johnston
Journal:  J Clin Endocrinol Metab       Date:  1979-10       Impact factor: 5.958

View more
  10 in total

1.  The infusion of somatostatin reduces the arginine-vasopressin response to insulin-induced hypoglycemia in man.

Authors:  P Chiodera; A Gnudi; L Bianconi; L Camellini; G Rossi; P Muzzetto; F Fagnoni; L Schianchi; R Volpi; V Coiro
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

2.  Endogenous opioid mediation of somatostatin inhibition of arginine vasopressin release evoked by insulin-induced hypoglycemia in man.

Authors:  P Chiodera; V Coiro
Journal:  J Neural Transm Gen Sect       Date:  1991

3.  Metergoline, naloxone, and sodium valproate did not modify arginine vasopressin response to insulin-induced hypoglycemia in man.

Authors:  P Chiodera; A Gnudi; R Volpi; L d'Amato; C Marchesi; G Pioli; P Muzzetto; A Castelli; L Bianconi; R Minelli
Journal:  J Endocrinol Invest       Date:  1988-05       Impact factor: 4.256

4.  Different effects of metoclopramide and domperidone on arginine-vasopressin secretion in man.

Authors:  P Chiodera; R Volpi; R Delsignore; C Marchesi; G Salati; L Camellini; G Rossi; V Coiro
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

5.  Increase by naloxone of arginine vasopressin and oxytocin responses to insulin-induced hypoglycemia in obese men.

Authors:  V Coiro; L Capretti; G Speroni; A Castelli; L Bianconi; U Cavazzini; A Marcato; R Volpi; P Chiodera
Journal:  J Endocrinol Invest       Date:  1990-10       Impact factor: 4.256

6.  Inhibitory effect of dexamethasone on the oxytocin response to insulin-induced hypoglycemia in normal men.

Authors:  P Chiodera; R Volpi; A Caiazza; C Davoli; C Marchesi; C Papadia; L Capretti; R Bocchi; V Coiro
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

7.  Oxytocin response to insulin-induced hypoglycemia in obese subjects before and after weight loss.

Authors:  V Coiro; M Passeri; C Davoli; L d'Amato; G Gelmini; F Fagnoni; L Schianchi; M Bentivoglio; R Volpi; P Chiodera
Journal:  J Endocrinol Invest       Date:  1988-02       Impact factor: 4.256

8.  5-HT3 serotonergic receptor mediation of hypoglycemia-induced arginine-vasopressin but not oxytocin secretion in normal men.

Authors:  R Volpi; P Chiodera; N Giuliani; L Capretti; G Caffarri; M G Magotti; V Coiro
Journal:  J Endocrinol Invest       Date:  1998-01       Impact factor: 4.256

9.  Effect of naloxone on somatostatin inhibition of arginine vasopressin response to physical exercise in normal men.

Authors:  V Coiro; A Casti; P Rubino; G Manfredi; M L Maffei; E Volta; S Cataldo; A Melani; G Saccani Jotti; P Chiodera
Journal:  J Neural Transm (Vienna)       Date:  2008-02-08       Impact factor: 3.575

Review 10.  Measuring Oxytocin and Vasopressin: Bioassays, Immunoassays and Random Numbers.

Authors:  G Leng; N Sabatier
Journal:  J Neuroendocrinol       Date:  2016-10       Impact factor: 3.627

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.